Medical dermatology company Botanix Pharmaceuticals Limited (ASX: BOT) is pleased to announce the receipt of Human Research Ethics Committee (HREC) approval and commencement of a patient study for its lead acne treatment product, BTX 1503. The announcement is available here for viewing.
Key announcement highlights:
For more information, please visit www.botanixpharma.com or follow us on Twitter @BotanixPharma
- Botanix receives Human Research Ethics Committee approval to commence BTX 1503 acne patient study
- Follows a successful Phase 1a study which showed excellent safety and tolerability of BTX 1503
- Rapid recruitment expected to facilitate study completion by the end of December 2017
- Positions BTX 1503 well for advancement into a Phase 2 safety and efficacy study under a FDA process in the USA in early 2018
- Forums
- ASX - By Stock
- Botanix Pharmaceuticals (ASX:BOT) – Botanix Commences BTX 1503 Acne Patient Study
Medical dermatology company Botanix Pharmaceuticals Limited...
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.5¢ |
Change
0.005(2.27%) |
Mkt cap ! $354.4M |
Open | High | Low | Value | Volume |
22.5¢ | 24.0¢ | 22.0¢ | $2.251M | 9.851M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 350473 | 22.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.0¢ | 140208 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 350473 | 0.220 |
7 | 487018 | 0.215 |
9 | 289379 | 0.210 |
9 | 965625 | 0.205 |
15 | 1384993 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.230 | 140208 | 4 |
0.235 | 249195 | 6 |
0.240 | 867464 | 5 |
0.245 | 362150 | 6 |
0.250 | 506315 | 12 |
Last trade - 16.10pm 29/03/2024 (20 minute delay) ? |
|
|||||
Last
22.5¢ |
  |
Change
0.005 ( 2.27 %) |
|||
Open | High | Low | Volume | ||
22.5¢ | 24.0¢ | 22.0¢ | 4728143 | ||
Last updated 15.58pm 29/03/2024 ? |
Featured News
BOT (ASX) Chart |